Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

McEachern

Showing results (411-420 of 494) with videos related to

Pageof 50
Sort By:
Journal of Medicinal Chemistry|September 2, 2021
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate CancerWeiguo Xiang, Lijie Zhao, Xin Han, et al.
Nature Chemical Biology|July 1, 2008
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivoScott A Yuzwa, Matthew S Macauley, Julia E Heinonen, et al.
Molecular and Cellular Biology|April 30, 2014
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signalingBo Cen, Ying Xiong, Jin H Song, et al.
Molecular Neurodegeneration|October 27, 2014
Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant miceScott A Yuzwa, Xiaoyang Shan, Bryan A Jones, et al.
Journal of Virology|September 29, 2006
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccineBruce A Mungall, Deborah Middleton, Gary Crameri, et al.
Journal of Medicinal Chemistry|March 25, 2017
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor RegressionBing Zhou, Jiantao Hu, Fuming Xu, et al.
Molecular Cancer Therapeutics|March 5, 2011
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentJianfeng Lu, Donna McEachern, Haiying Sun, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 6, 2002
Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse modelJohn Marshall, Kerry Anne McEachern, Julie A Cavanagh Kyros, et al.
Clinical Neurology and Neurosurgery|February 7, 2018
Streamlined triage and transfer protocols improve door-to-puncture time for endovascular thrombectomy in acute ischemic strokeAkash P Kansagra, Adam N Wallace, David R Curfman, et al.
Movement Disorders Clinical Practice|June 18, 2025
Developing an Outpatient Transdisciplinary Functional Movement Disorder Program: 1-Year ExperienceGabriela S Gilmour, Kayla Fritz, Joanne Stephen, et al.
Pageof 50

Showing results (411-420 of 494) with videos related to

Sort By:
Pageof 50
Journal of Medicinal Chemistry|September 2, 2021
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate CancerWeiguo Xiang, Lijie Zhao, Xin Han, et al.
Nature Chemical Biology|July 1, 2008
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivoScott A Yuzwa, Matthew S Macauley, Julia E Heinonen, et al.
Molecular and Cellular Biology|April 30, 2014
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signalingBo Cen, Ying Xiong, Jin H Song, et al.
Molecular Neurodegeneration|October 27, 2014
Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant miceScott A Yuzwa, Xiaoyang Shan, Bryan A Jones, et al.
Journal of Virology|September 29, 2006
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccineBruce A Mungall, Deborah Middleton, Gary Crameri, et al.
Journal of Medicinal Chemistry|March 25, 2017
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor RegressionBing Zhou, Jiantao Hu, Fuming Xu, et al.
Molecular Cancer Therapeutics|March 5, 2011
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentJianfeng Lu, Donna McEachern, Haiying Sun, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 6, 2002
Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse modelJohn Marshall, Kerry Anne McEachern, Julie A Cavanagh Kyros, et al.
Clinical Neurology and Neurosurgery|February 7, 2018
Streamlined triage and transfer protocols improve door-to-puncture time for endovascular thrombectomy in acute ischemic strokeAkash P Kansagra, Adam N Wallace, David R Curfman, et al.
Movement Disorders Clinical Practice|June 18, 2025
Developing an Outpatient Transdisciplinary Functional Movement Disorder Program: 1-Year ExperienceGabriela S Gilmour, Kayla Fritz, Joanne Stephen, et al.
Pageof 50